To print: Select File and then Print from your browser's menu

Title: In Recent Study, Canadian Men with Erectile Dysfunction and their Partners Prefer Cialis (Tadalafil) over Another Leading Treatment

"In Recent Study, Canadian Men with Erectile Dysfunction and their Partners Prefer Cialis (Tadalafil) over Another Leading Treatment"

MONTREAL, CANADA -- December 5, 2005 -- In the first ever Canadian study measuring both patient and partner preference and satisfaction with erectile dysfunction (ED) treatments, Cialis® (tadalafil) was preferred over Viagra® (sildenafil). In the study, both patients (58% to 70%) and their partners (65% to 75%) indicated that they preferred Cialis, after they either switched from sildenafil to Cialis or from Cialis to sildenafil. The findings were presented today at the 8th Congress of the European Society for Sexual Medicine in Copenhagen, Denmark. Almost 2,800 Canadians Provide a 'Real World' Perspective This study was designed to obtain data in a 'real world' clinical setting about treatment preference and satisfaction of both men and their partners when they switched from one treatment to another. The study was conducted at 266 research sites across Canada and involved >2,600 patients who signed up and >2,400 patients and >320 partners who completed both visits. Patients who planned to change treatment from either sildenafil or Cialis to the other drug were invited to participate. Their level of satisfaction with their existing treatment was measured using the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire, both patient and partner versions, at their first physician visit. Treatment preference by patients and their partners was measured at the second visit together with physician-rated patient preference. More than 98% of the patients completed the study. While overall treatment satisfaction scores were higher for Cialis than sildenafil, the level of satisfaction was pronounced amongst partners, suggesting that the benefits of Cialis are particularly appealing to this group. "In treatment of men with erectile dysfunction, the goal is to find a treatment that works well and, more importantly, satisfies both patients and their partners," said Dr. Carrier, Urologist, CUSM-Royal Victoria Hospital. "This study may provide Canadian physicians with a stronger understanding of patient and partner preference and satisfaction levels. The information gained by these findings may assist physicians to help men and their partners find the treatment option that works best for them." Recent guidelines by the American Association for Clinical Endocrinologists recommend that partners be involved in treatment decisions and early on in the process[1] Guay et al. Endrocin Pract, 2003.[1]. In this study, it was found that almost three quarters of men informed their partner of their use of an ED treatment but only 12% of partners actually participated in the consultation process with the physician. About Erectile Dysfunction ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. As of 2004, it is estimated that approximately 189 million men worldwide have ED.[2] Data were extrapolated from Feldman HA, Goldstein I, Hatzichistou DG, Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, Journal of Urology. Vol 151, 54-61, January 1994 and World Population Projection Program of United Nations (2002 Revisions) with indirect standardization.[2] Experts believe that 80 - 90% of ED cases are related to a physical or medical condition, such as diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 - 20% are due to psychological causes.[3] Shabsigh R (2002). Back to Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington.[3],[4] Diseases and Conditions: Impotence, http://www.impotence.org/FAQ/index.asp Data accessed 11.20.03.[4] In many cases, however, both psychological and physical factors contribute to the condition.[5] Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813.[5] About Cialis Cialis, approved by Health Canada in September 2003, and available for the first time in Canadian pharmacies November 2003, is the first oral ED treatment shown to be effective for up to 36 hours after taking the drug. Cialis will not cause an erection without sexual stimulation. Cialis can be taken without regard to food. Cialis is currently available in approximately 100 countries. More than 3.5 million patients worldwide have been treated with Cialis since its first introduction in February 2003. Men should discuss their health status with their doctors to ensure Cialis is right for them and that they are healthy enough for sexual activity. The most commonly reported side effects with Cialis are headache, upset stomach, nasal congestion, back pain, muscle ache, dizziness and flushing. The side effects reported with Cialis were generally mild or moderate and transient. As with other PDE5 inhibitors, the use of Cialis is contraindicated in patients who are taking nitrates and should not be used in men who have cardiac disease for whom sexual activity is not advisable. Men should not drink alcohol in excess with Cialis. Cialis does not protect a man or his partner from sexually transmitted diseases, including HIV. REFERENCES: 1. Guay et al. Endrocin Pract, 2003. 2. Data were extrapolated from Feldman HA, Goldstein I, Hatzichistou DG, Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, Journal of Urology. Vol 151, 54-61, January 1994 and World Population Projection Program of United Nations (2002 Revisions) with indirect standardization. 3. Shabsigh R (2002). Back to Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington. 4. Diseases and Conditions: Impotence, http://www.impotence.org/FAQ/index.asp Data accessed 11.20.03. 5. Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813. Cialis is a trademark of Lilly ICOS LLC. Viagra® is a trademark of Pfizer. SOURCE: Lilly ICOS LLC

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.